drugset / Trial / NCT00726037

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

NCT00726037

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.

Timeline

Start
2008-10
Primary completion
2012-01
Completion
2012-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject denileukin diftitox Protein / enzyme biologic 9 ug/kg Intravenous